If you look at Bell's valuation and remove the probability ratios (assuming P3 success and FDA approval) they have Neuren valued at $800m on Trofinetide for Retts and Fragile X alone. Success of the Trofinetide molecule then adds weight to the potential of NNZ-2591 the value of which needs to be added to the $800m plus the multitude of other potential applications for either drug.
I my view if it isn't $1B minimum then we haven't achieved full value and the board should continue down the P3 path until we do. I would be disappointed if the sold out early for less than this. I think the shareholders have shown they are in for the long haul and we should run the course to unlock full potential.
- Forums
- ASX - By Stock
- Neuren - Cracking the $200m m/cap again.
If you look at Bell's valuation and remove the probability...
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.78 |
Change
0.165(1.21%) |
Mkt cap ! $1.763B |
Open | High | Low | Value | Volume |
$13.60 | $13.85 | $13.51 | $887.1K | 64.59K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 68 | $13.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.79 | 582 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 84 | 13.800 |
5 | 493 | 13.790 |
6 | 2041 | 13.780 |
4 | 502 | 13.770 |
5 | 543 | 13.760 |
Price($) | Vol. | No. |
---|---|---|
13.810 | 84 | 5 |
13.820 | 1125 | 8 |
13.830 | 434 | 3 |
13.840 | 1701 | 8 |
13.850 | 497 | 3 |
Last trade - 11.19am 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |